In chronic LCMV-Cl13 infection, we have shown a greater therapeutic potential for LCMV-specific CXCR5+CD8 T cells than the CXCR5− subset upon adoptive transfer to chronically infected mice, as well as synergistic effects that reduce the viral load when combined with anti-PD-L1 treatment (45). This evidence concerns the gene CD8A and infection.